Pharmaceutical Industry Examined in New GBI Research Premium Reports Published at

07 Oct 2011 • by Natalie Aster

Market Publishers Ltd informs that new GBI Research's Pharmaceutical Industry Reports have been added to its catalogue:

Contraceptives Market to 2017 - Hormonal Contraceptives and Strong Pipeline to Drive the Growth in Future.

The global hormonal contraceptive market is a fast growing market, with oral contraceptives considered to be the most common method of avoiding unplanned pregnancies. In 2010, the global contraceptives market was valued at $15.5 billion and is forecast to grow to $19.2 billion by 2017, which represents a growth rate of 3..1% from 2010 - 2017. According to a report by the Guttmacher Institute, the number of women who require publicly funded contraceptives increased by one million from 2001 - 2004. An increase in the number of women who require publicly funded contraception indicates an increasing awareness among women of contraceptive methods. The use of contraceptive devices such as condoms, intrauterine devices and vaginal rings will increase market value. Increasing awareness will accelerate growth in the contraceptive market by 2017. As a result, market growth will continue and this will attract the attention of pharmaceutical companies.

HIV/AIDS Therapeutics Market to 2017 - Superior Combination Therapies and Decreasing Mortality to Sustain Market Growth Despite Major Patent Expiries.

The HIV market is a growing market dominated by the US. The growth rate is likely to decline from 2012 due to the impact of the patent expiries of key drugs. The market is driven by an increase in the treatment seeking rate as well as the introduction of new drugs such as Atripla as part of HAART (Highly Active Anti-Retroviral Therapy). The HIV market is currently growing at a slower rate compared to previous years. This is primarily due to the patent expiries of major drugs such as Sustiva (efavirenz) and Combivir (lamivudine and zidovudine) in 2012. Other drugs such as Epivir (lamivudine), Epzicom (abacavir lamivudine), Trizivir (abacavir zidovudine lamivudine), Ziagen (abacavir), Invirase (saquinavir) and Lexiva (fosamprenavir) went off patent in 2009 and 2010. However, the impact of these patent expiries will be offset by the increased use of new drugs which are more effective in tackling disease progression. The sales of new drugs such as Atripla have increased at a calculated annual growth rate (CAGR) of 136% over the last three years.

Published: Okt’11
Per Report Price: US$ 3,500 (Single User License)

To order the report or ask for sample pages contact


MarketPublishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax: +44 207 900 3970